Corcept Therapeutics reported phase 3 data showing that relacorilant, an oral selective glucocorticoid receptor antagonist, reduced the risk of death by 35% in platinum‑resistant ovarian cancer when added to chemotherapy. The company said the OS result met the trial’s key secondary endpoint and followed an earlier PFS finding, prompting a sharp share rebound and heightened expectations ahead of a pending FDA review. Analysts project relacorilant could access a multi‑hundred‑million‑dollar market if approved; some forecasts extend into the billions over time depending on label expansion. Corcept’s program faces regulatory history including a prior CRL for a different indication, but the new survival data materially strengthen its approval case and commercialization outlook.